Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
To back, or back away from, digital health?
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
Akili plays the Spac game for $1bn
But, judging by similar transactions, the valuation might not stay that high for long.